Keytruda misses survival endpoints in Phase III HCC trial

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab missed the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) in the Phase III KEYNOTE-240 trial to treat advanced hepatocellular carcinoma. Merck declined to disclose if KEYNOTE-240 was an FDA-required

Read the full 412 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE